UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT

(DATE OF EARLIEST EVENT REPORTED)

~~December~~November 1, ~~22, 2006~~2007

INTEGRATED PHARMACEUTICALS, INC

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

COMMISSION FILE NUMBER 000-50960

Integrated Pharmaceuticals, Inc.

(Exact name of small business issuer in its charter)

Idaho	04-3413196
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

310 Authority Drive

Fitchburg, MA 01420

(Address of principal executive offices) (Zip Code)

(978) 696-0020

(Issuer'’s telephone number, including area code)

~~Item~~Check the appropriate ~~1.01.~~box ~~Entry~~below ~~into~~if athe ~~Material~~Form ~~Definitive~~8-K ~~Agreement.~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~On December~~¨ ~~22,~~Written ~~2006,~~communication ~~Integrated~~pursuant Pharmaceuticals Inc. (the “Company”), entered into an Investment Agreement and a Registration Rights Agreement (the “Agreements”) with Dutchess Private Equities Fund, L.P. (“Dutchess”). Under the Agreements, the Company can require Dutchess to ~~purchase~~Rule up425 tounder ~~$10,000,000 of~~ the Company’s common stock over a three year period provided that there is then in effect a registration statement covering the public resale of the shares of purchased by Dutchess from the Company. In connection with entering into the Agreement, the Company has engaged US EURO Securities, ~~Inc.~~Act (~~“Euro”)~~17 toCFR ~~act as placement agent in the transaction, and paid Euro a fee of $1,000 in connection with this engagement~~230. ~~The Company had previously paid Dutchess a document preparation fee of $15,000 in connection with the Agreement.~~425)

~~The Agreement~~¨ ~~may~~Soliciting bematerial ~~drawn~~pursuant ~~down by the Company in amounts up~~ to ~~$250,000,~~Rule ~~provided that the drawn~~14a-~~down~~12 ~~does~~under ~~not exceed 200% of~~ the ~~average~~Exchange ~~daily~~Act ~~trading volume of the Company’s stock during the tem~~ (~~10)~~17 ~~days~~CFR ~~prior to the notice to Dutchess of the draw-down~~240. ~~At the closing of each draw~~14a-~~down (which will take place not later than eight trading days after notification by the Company~~12) the Company will issue to Dutchess a number of shares of its common stock equal to the amount of the draw-down divided by 94% of the lowest daily closing price of the Company’s common stock during the five trading days following the draw-down notice to Dutchess. At each of the first six closings, the Company is required to pay $1,500 of the amount of the draw-down to Euro. The Company is not obligated to make any draw-downs under the Agreement, and will not pay any additional fees to Dutchess or Euro if it does not do so. The issuance by the Company of more than approximately 25 million shares of its common stock to Dutchess will require prior stockholder approval. This figure will increase by approximately 3.94 million shares if the $2.50 warrants that are scheduled to expire on December 31, 2006 expire unexercised.

~~The Company~~¨ ~~may~~Pre-commencement ~~not~~communications ~~issue~~pursuant ~~Dutchess~~to aRule ~~number~~14d-2(b) ofunder ~~shares of its common stock such that it would beneficially own greater than 4.99% of~~ the ~~Company’s~~Exchange ~~outstanding~~Act ~~shares of~~(17 ~~common~~CFR ~~stock~~240. 14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02.

Appointment of Principal Officers

On November 1, 2007, the Board of Directors elected Peter Featherston as President and Chief Executive Officer (CEO) of Integrated Pharmaceuticals, Inc. The Board also increased the size of the Board to six (6) and filled the vacancy created thereby by electing Mr. Featherston to the Board.

There are no arrangements or understandings between Mr. Featherstone and any other person pursuant to which Mr. Featherston was elected to the Board and is not expected to be named to any of the Board’s committees other than the Audit committee. There have been no transactions between Mr. Featherston and the Company during the last two years involving $60,000 or more. There is no material plan, contract or arrangement to which Mr. Featherston is a party (or in which he participates) that was entered into or amended in connection with his appointment as CEO or election to the Board.

Mr. Featherston’s compensation as CEO will be based upon a $90,000 annual salary plus a bonus of $20,000 if the Company achieves certain sales objectives. He will be issued a warrant, exercisable at $0.20 per share, for 500,000 shares of the Company’s common stock. The warrant will vest as the Company achieves certain sales objectives. Mr. Featherston will be included in the Company’s health insurance program. It is expected that Mr Featherston will receive a second year salary of $120,000 and a $30,000 bonus and warrant for 250,000 shares at .60 cents and in year three a salary of $150,000 and a $40,000 bonus and warrant of 125,000 shares at $1.20.

Mr. Featherston from 1982 to 2005, was co-founder, co-owner and chief operating and marketing officer of RISMEDIA, a privately held, national real estate media company based in Norwalk, Connecticut. In 2006 and 2007, Mr. Featherston acted as a business consultant/broker and created works of art with notable Americans.

Mr. Featherston is not a director of any other public company, and he is not related to any other officer or director of the Company.

The Company intends to enter into a written employment agreement with Mr. Featherston, but has not yet done so.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	INTEGRATED PHARMACEUTICALS, INC.
DATE: December 26, 2006	By:	/s/ Chinmay Chatterjee
DATE: November 5, 2007	By:	/s/ Peter Featherston
		Chinmay Chatterjee
		Peter Featherston
		President and CEO
		President and Chief Executive Officer

Filing Compare · INTEGRATED PHARMACEUTICALS INC